Neuropace, Inc.

Stage 4 · Declining · week 9

As of Oct 22, 2026, Neuropace is in Stage 4, the downtrend phase, now in week 9 (since Aug 20, 2026). It closed at $13.14, 31.9% below its 52-week high and below its 200-day average, which is falling.

NeuroPace, Inc. operates as a medical device company in the United States. More about the company

$13.14

+0.69% today

$451M · Small cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is NPCE early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S2 34w

S2 14w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S3 1w → S2 34w → S3 8w → S4 10w → S1 5w → S4 7w → S1 5w → S2 14w → S3 6w → S2 6w → S3 4w → S4 9w → S1 8w → S2 13w → S3 9w → S2 12w → S3 4w → S4 9w current

Total tracked: 165 weeks across 18 stage runs.

NPCE among Medical Devices31st of 141 by relative strength

All 141 →

Stocks in Medical Devices ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	TXG10x Genomics, Inc.	Stage 2 · wk 48	99	−7.8%
2	RCELAvita Medical, Inc.	Stage 2 · wk 13	98	+40.8%
3	BFLYButterfly Network, Inc. Class A	Stage 2 · wk 26	98	−26.0%
4	HAEHaemonetics Corporation	Stage 2 · wk 17	96	+8.7%
5	GKOSGlaukos Corporation	Stage 2 · wk 25	96	+15.1%
6	AXGNAxogen, Inc.	Stage 3 · wk 2	95	−15.3%
7	NEOGNeogen Corporation	Stage 2 · wk 14	95	−11.7%
8	BVSBioventus Inc. Class A	Stage 2 · wk 15	95	+10.5%
…31	NPCENeuropace, Inc.	Stage 4 · wk 9	71	−7.5%

vs 52W High

-31.9%

$9.40 lo$19.29 hi

31.9% below 52W high, ongoing decline

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 9

1w13w26w

Week 9, established downtrend

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-13.0%

200 DMA: $15.10 · sloping down

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

0.76x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-7.5%

-11.3%

-22.1%

YTD

-13.4%

+21.8%

Scan Membership

Breakout Watch

Latest: 2025-05-19

4 appearances in last 60 days. First seen: 2023-03-17.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S4

Wk 9 · Vol 0.76x

2026-10-21S4

Wk 9 · Vol 0.39x

2026-10-20S4

Wk 9 · Vol 0.86x

2026-10-19S4

Wk 9 · Vol 0.86x

2026-10-16S4

Wk 9 · Vol 1.12x

2026-10-15S4

Wk 8 · Vol 0.60x

2026-10-14S4

Wk 8 · Vol 0.61x

2026-10-13S4

Wk 8 · Vol 0.42x

2026-10-12S4

Wk 8 · Vol 0.39x

2026-10-09S4

Wk 8 · Vol 0.44x

2026-10-08S4

Wk 7 · Vol 0.83x

2026-10-07S4

Wk 7 · Vol 0.74x

Moving averages & range

50 DMA

$13.87

200 DMA

$15.10

52W High

$19.29

52W Low

$9.40

5D Low

$12.24

Resistance levels (recent highs)

20d High

$14.15

60d High

$15.19

120d High

$19.29

250d High

$19.29

Next resistance

+7.7%

to 20d High

ROE

-103.3%

Profit margin -17.9%

Dividend Yield

0.00%

P/B 37.9

Neuropace: quick answers

What stage is Neuropace in?

As of Oct 22, 2026, Neuropace (NPCE) is in Stage 4, the downtrend phase. It entered Stage 4 on Aug 20, 2026 and is in week 9. What the four stages mean

Is Neuropace in an uptrend?

No. Neuropace is in a Stage 4 downtrend. It trades 13.0% below its 200-day average, which is falling.

How far is Neuropace from its 52-week high?

Neuropace closed at $13.14 on Oct 22, 2026, 31.9% below its 52-week high of $19.29. Its 52-week low is $9.40.

How has Neuropace performed over the past year?

As of Oct 22, 2026, Neuropace is up 21.8% over the past year and down 13.4% so far in 2026.

Which sector and industry is Neuropace in?

Neuropace is in the Medical Devices industry, part of the Health Care sector.

About this companyHealth Care· Medical Devices

NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant focal epilepsy. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. In addition, the company provides physician tablet which is used for prescribing and managing clinicians for programming implanted devices and managing patient care; and patient data management system, a secure online database that collects data that have been recorded by the RNS System; and nSight Platform, which provide clinicians with personalized patient reports, as well as programming suggestions. It sells its products to hospital facilities for initial RNS System implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.